Developing a new class
of autoimmune drugs.
Leaders in live
biotherapeutic drug
development.
State-of-the-art
biopharmaceutical
manufacturing.

Welcome to
Servatus

Servatus is an Australian biopharmaceutical company developing dual drug platforms, aiming to deliver first-line and adjunct treatments for select autoimmune, inflammatory and infectious conditions.
Learn more about Servatus >
img2

Live Biotherapeutics
(LBPs)

Servatus has isolated and characterised select microbial species and
undertaken extensive pre-clinical investigations to develop highly
defined medicines that target autoimmune, inflammatory
and chronic conditions.

Human clinical trials currently underway are expected to confirm the
clinical utility of these medicines, with the aim to advance safe and
effective treatments.

A key project is the development of pharmaceutical-grade live
biotherapeutics agents derived from micro-organisms predominantly
of bacterial origin.
Live biotherapeutic research >
img3

Engineered Protein

As current drugs reach their limit in providing long-term efficacy and
safety for patients, harnessing new modes of action provides the
greatest opportunity to advance medical therapies for the future.

Servatus' research is directed at improving the specific characteristics
of select proteins to provide safe, effective treatments for immune
-mediated inflammatory diseases. Servatus targets key features of
the protein to improve its clinical efficacy and to complement existing
drug therapies.

Servatus has engineered a modified protein selected on its inherent
immune-modulating ability, with anticipated improvements in clinical
efficacy and commercial delivery.
Autoimmune research >
img4

What We Do

Learn more about the latest news in Australian Biopharmaceuticals Research and our work in progressing the science for a better autoimmune drugs.
View our works >Latest news >